scarica pdf

Transcript

scarica pdf
Test biochimici:
prevedere la preeclampsia
Paolo Accorsi
Carpi
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
In a normal pregnancy, normal placentation and subsequent spiral artery
remodeling occurs, wherein narrow-caliber high-resistance vessels transform
into wide-caliber low-resistance vessels owing to the replacement of spiral
arterial vascular endothelial cells and vascular smooth muscle resulting from
extravillous trophoblasts invading the decidua.
This prevents spiral arterial constriction and maintains abundant blood flow,
leading to increased oxygen partial pressure in the placental intervillous
space
2
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
… balance between antiangiogenic and angiogenic factors should be
investigated to elucidate the various pathological features of preeclampsia.
Their accurate evaluation is needed to investigate not only antiangiogenic
factors (such as sFlt-1 and sEng) and angiogenic factors (such as vascular
endothelial growth factor, placental growth factor and transforming growth
factor-beta) but also the expression level of their receptors such as Flt-1 and
Eng.
The levels of syncytiotrophoblast microparticles (STBMs), which have
proinflammatory and antiangiogenic activity, are significantly higher in
preeclampsia patients…
3
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Preeclampsia is characterized by abnormal implantation/placentation before
the abnormal placental bed vascular remodeling, leading to placental hypoxia,
secretion of proinflammatory cytokines, and the release of antiangiogenic and
angiogenic factors and of syncytiotrophoblast microparticles (STBMs). Both
antiangiogenic factors and STBMs have been demonstrated to play an
important role in the development of the maternal syndrome of PE.
… a poorly perfused placenta, as observed in the first stage, is not sufficient
to cause the maternal syndrome
…it remains difficult to explain the various pathogenic features of
preeclampsia from the viewpoint of antiangiogenic factors and/or STBMs…
4
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
…for elucidating the various physiological features of preeclampsia, it is necessary
to accurately evaluate the balance between the plasma levels of antiangiogenic
and angiogenic factors and the expression levels of their receptors.
Acta Obstet Gynecol Scand 2014; 93: 959–964
5
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
…Because sFlt-1 is a soluble receptor of vascular endothelial growth factor (VEGF),
whereas PlGF, a factor belonging to the VEGF family, is a ligand of sFlt-1, the
overproduction of sFlt-1 and low levels of PlGF occurring in preeclampsia lead to
reduced free VEGF levels, thereby suppressing placental angiogenesis.
…Even if sFlt-1 production is not increased, reduced VEGF production may
therefore result in the onset of preeclampsia. Moreover, even if VEGF production
increases adequately, a larger increase in sFlt-1 levels may lead to the onset of
preeclampsia through a decrease in free VEGF.
These reports indicate the variable pathological features of preeclampsia and
emphasize the importance of accurately examining the balance of antiangiogenic
and angiogenic factors, including the expression levels of their receptors
Acta Obstet Gynecol Scand 2014; 93: 959–964
6
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Manisha Kar. Role of Biomarkers in Early Detection of Preeclampsia. Journal of Clinical and Diagnostic
Research. 2014 Apr, Vol-8(4): BE01-BE04
7
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
The most widely studied serum markers for PE are vascular endothelial growth factor
(VEGF) and placental growth factor (PlGF) and their antagonists, namely, soluble fmslike tyrosine kinase 1 (sFlt-1, also known as sVEGFR1), and soluble endoglin (sEng)
§ sFlt-1 circulates freely in the serum, where it binds and neutralizes VEGF and PlGF.
The sFlt-1 levels are correlated directly with severity of disease and they are
inversely related with time to onset of proteinuria and hypertension.
§ sEng is a potential anti-angiogenic factor … which affects production of nitric oxide
(NO), vasodilation, and capillary formation by endothelial cells in vitro. It has been
reported that sEng is elevated in second-trimester maternal serum in patients who
are destined to develop severe preeclampsia…
Manisha Kar. Role of Biomarkers in Early Detection of Preeclampsia. Journal of Clinical and Diagnostic
Research. 2014 Apr, Vol-8(4): BE01-BE04
8
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
§ Both VEGF and PlGF, one of the variants of VEGF, are key players in this process. The
level of free PlGF in blood is found to be decreased in PE, though normally, its
concentration increases during first 30 weeks of gestation. The low concentration of
free VEGF in PE is difficult to measure by the commercially available ELISA kits.
§ Placental protein 13 (PP-13) is a relatively small dimer protein. It probably has an
immunobiological function at the foeto-maternal interface and in maternal vascular
remodelling. The levels of PP-13 in serum gradually increase in normal pregnancy, but
abnormally low levels of PP-13 were detected in first trimester serum samples of
women who subsequently developed preeclampsia and IUGR. Combined measuring
of maternal serum PP-13 and median uterine artery pulsatility index by using
ultrasound early in pregnancy seems to predict severe PE.
Manisha Kar. Role of Biomarkers in Early Detection of Preeclampsia. Journal of Clinical and Diagnostic
Research. 2014 Apr, Vol-8(4): BE01-BE04
9
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
§ Pregnancy-associated plasma protein-A (PAPP-A) is a syncytiotrophoblast derived
metalloproteinase, which enhances the mitogenic function of the insulin-like growth
factors by cleaving the complex formed between such growth factors and their
binding proteins. It was reported that decreased plasma levels of PAPP-A seen in
first trimester were associated with PE.
The insulin-like growth factor system is believed to play an important role in placental
growth and development; it is therefore not surprising that low serum PAPP-A is
associated with a higher incidence of PE. Increased level of maternal serum PAPP-A
has been observed in established PE.
Manisha Kar. Role of Biomarkers in Early Detection of Preeclampsia. Journal of Clinical and Diagnostic
Research. 2014 Apr, Vol-8(4): BE01-BE04
10
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Manisha Kar. Role of Biomarkers in Early Detection of Preeclampsia. Journal of Clinical and Diagnostic
Research. 2014 Apr, Vol-8(4): BE01-BE04
11
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
PE & esiti: possibili fattori confondenti
•
E’ una patologia sola o sono 2 quadri diversi (“early” & “late”)?
•
Quali esiti si devono considerare?
-Parto pretermine? <34w? Lo decidiamo spesso noi e/o i neonatologi…
-FGR? Gli studi sono su popolazioni miste, di diverse etnie variamente
“mescolate”. PE senza FGR, FGR senza PE…
•
Incidenza della patologia varia tra etnie (> presenza in afro-caraibiche e
sud-asiatiche vs caucasiche).
•
Per la bassa prevalenza della patologia, almeno quella più rilevante
clinicamente, occorrono grandi numeri per avere risultati significativi.
12
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Test biochimici per prevedere la preeclampsia?
13
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Prevedere la preeclampsia?
Fetal Diagn Ther 2012;32:171–178 (FMF)
Esito: Preeclampsia con parto <34W (FPR 10%), Detection Rate
Caratteristiche materne:
50.5%
Caratteristiche materne + PI uterine:
75.2%
Caratteristiche materne + MAP:
72.9%
Caratteristiche materne + MAP + PI u.:
89.7%
Nota: selezione della popolazione senza biochimica…
14
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Prevedere la preeclampsia?
Fetal Diagn Ther 2013;33:8–15 (FMF)
Esito: Preeclampsia con parto <34W (FPR 10%), Detection Rate
[1426 donne che hanno sviluppato PE ad ogni epoca di gravidanza]
Caratteristiche materne:
50.5%
Caratteristiche materne + MAP + PI u.:
89.7%
“
+ MAP + PI u. + PAPP-A:
92.5%
“
+ MAP + PI u. + PAPP-A + PlGF:
96.3%
Nota: potrebbe identificare la quasi totalità delle PE < 34 W,
Quindi dovrebbe/potrebbe essere un buon test di screening
15
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Quale modalità di selezione della popolazione?
Fetal Diagn Ther 2013;33:8–15 (FMF)
Esito: Preeclampsia con parto <34W  214 su 57458 (0,4%)
[1426 donne che hanno sviluppato PE ad ogni epoca di gravidanza]
Caratteristiche materne:
108 si (106 no)
Caratteristiche materne + MAP + PI u.:
192 si (22 no)
“ + MAP + PI u. + PAPP-A:
198 si (16 no)
“ + MAP + PI u. + PAPP-A + PLGF:
206 si (8 no)
16
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Review. LC Poon, KH Nicolaides. Prenatal Diagnosis 2014, 34, 618–627
17
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Review. LC Poon, KH Nicolaides. Prenatal Diagnosis 2014, 34, 618–627
18
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Dalla clinica alla statistica…
It has been demonstrated that maternal demographic characteristics, including
medical and obstetric history, are potentially useful in screening for PE only
when the various factors are incorporated into a combined algorithm derived
by multivariate analysis. Certain variables, including advancing maternal age
over 35 years, increasing weight, Afro-Caribbean and South Asian racial origin,
previous pregnancy with PE, conception by in vitro fertilization (IVF) and a
medical history of chronic hypertension, preexisting diabetes mellitus, and
systemic lupus erythematosus or antiphospholipid syndrome, increase the risk
for development of PE. Estimated detection rate of PE requiring delivery before
34 weeks’ gestation in screening by maternal factors is 51% at false-positive
rate of 10%.
LC Poon, K H Nicolaides. Early Prediction of Preeclampsia. Obstetrics and Gynecology International.
Volume 2014, Article ID 297397http://dx.doi.org/10.1155/2014/297397
19
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Dalla biochimica alla statistica…
In biochemical testing, it is necessary to make adjustments in the measured maternal
serum metabolite concentration to correct for certain maternal and pregnancy
characteristics as well as the machine and reagents used for the assays, and the serum
metabolite concentration is then expressed in a multiple of the expected median
(MoM) of the normal.
First-trimester maternal serum concentrations of PAPP-A and PlGF have shown to be
affected by gestational age at screening, maternal weight, racial origin, cigarette
smoking, conception by IVF, nulliparity and pre-existing diabetes mellitus. In addition,
serum PlGF is also affected by maternal age.
Consequently, the measured concentrations of PAPP-A and PlGF must be adjusted for
these variables before comparing results with pathological pregnancies.
The MoM values of PAPP-A and PlGF are significantly reduced at 11–13 weeks’
gestation in women who subsequently develop PE.
LC Poon, K H Nicolaides. Early Prediction of Preeclampsia. Obstetrics and Gynecology International.
Volume 2014, Article ID 297397http://dx.doi.org/10.1155/2014/297397
20
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Conclusioni:
• Using multivariate analysis in a large study population, we have identified the
independent predictive value of each obstetric, demographic and maternal
serum marker.
• Mathematical modelling suggests high predictive ability at a reasonable falsepositive rate; prospective studies are underway to confirm the predictive
values. ( ? ? ? ? )
LC Poon, K H Nicolaides. Early Prediction of Preeclampsia. Obstetrics and Gynecology International.
Volume 2014, Article ID 297397http://dx.doi.org/10.1155/2014/297397
21
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
King’s College
Vs
???
Resto del Mondo
22
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
The aim of this study is to validate the Fetal Medicine Foundation (FMF)
multiple logistic regression algorithm for prediction of risk of pre-eclampsia in
an Australian population. This model, which predicts risk using the population
rate of pre-eclampsia, a variety of demographic factors, mean maternal arterial
blood pressure (MAP), uterine artery PI (UtA PI) and pregnancy-associated
plasma protein A (PAPP-A), has been shown to predict early-onset
preeclampsia (delivery < 34 weeks) in 95% of women at a 10% FPR.
Conclusions: This study shows that the FMF early pre-eclampsia algorithm is
effective in an Australian population
FJ Park et al. Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of
pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology 2013; 53: 532–539
23
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Objective. To investigate the performance of a multivariable model combining
a priori clinical characteristics and biomarkers to detect, early in pregnancy,
women at higher risk of developing pre-eclampsia (PE).
Methods. We selected a priori clinical characteristics and promising markers to
create multivariable logistic regression models: body mass index (BMI), mean
arterial pressure (MAP), placental growth factor (PlGF), soluble Fms-like
tyrosine kinase-1 (sFlt-1), pregnancy-associated plasma protein A (PAPP-A) and
inhibin A.
Results. At false-positive rates of 10%, the estimated detection rates were
between 39% (19–59%) and 50% (34–66%).
Conclusions. In a population with a low prevalence of preterm PE (0.2%), a
multivariable risk algorithm using an a priori combination of clinical
characteristics and biochemical markers did not reach a performance justifying
clinical implementation as screening test early in pregnancy.
Y Giguère, et al. Screening for pre-eclampsia early in pregnancy. BJOG 2014; DOI: 10.1111/1471-0528.13050.
Settembre 2014 (Canada)
24
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Objective: To develop a predictive model for preeclampsia using clinical,
biochemical (PlGF) and ultrasound markers (UtA PI) during the first trimester
of pregnancy.
Results: Different combined models were generated by logistic regression
analysis, and the detection rate (with a fixed 10% false-positive rate) was 47%
and 29% for early- and late-onset pre-eclampsia, respectively.
Conclusion: Regression models which include maternal characteristics, UtA
Doppler and PlGF can apparently predict approximately half of pregnancies
that will be complicated by early-onset pre-eclampsia. We believe more
research in several areas is needed to aid in the creation of a better and more
population-specific screening test for pre-eclampsia during the first trimester
of pregnancy.
M. Parra-Cordero et al. Prediction of early and late pre-eclampsia from…
Ultrasound Obstet Gynecol 2013; 41: 538–544 (Cile)
25
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Am J Obstet Gynecol 2013;208:203.e1-10
26
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Nota >>> FMF: Caratteristiche materne + MAP + PI u.: 89.7% (FPR 10%)
Am J Obstet Gynecol 2013;208:203.e1-10
27
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
28
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
CONCLUSION: A multivariable analysis of clinical data
and biochemical markers in the first trimester did not identify a
model that had clinical utility for predicting
preeclampsia in a nulliparous population at low risk.
29
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Objective: To evaluate the performance of published first-trimester prediction
algorithms for pre-eclampsia (PE) in a prospectively enrolled cohort of women.
Results: Six early and two late PE prediction algorithms were applicable to
871–2962 women, depending on the variables required. The prevalence of early
PE was 1.0–1.2% and of late PE was 4.1–5.0% in these patient subsets. One
early PE prediction algorithm performed better than in the original publication
(80% detection rate (DR) of early PE for 10% false-positive rate (FPR)); the
remaining five prediction algorithms underperformed (29–53% DR).
Conclusion: First-trimester prediction algorithms for PE share a high negative
predictive value if applied to an external population but underperform in their
ability to correctly identify women who develop PE. Further research is
required to determine the factors responsible for the suboptimal external
validity
N. Oliveira et al. First-trimester prediction of pre-eclampsia: external validity of algorithms in a prospectively
enrolled cohort. Ultrasound Obstet Gynecol 2014; 44: 279–285 (Baltimora, USA)
30
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Objective: To evaluate the performance of published first-trimester prediction
algorithms for pre-eclampsia (PE) in a prospectively enrolled cohort of women.
Results: Six early and two late PE prediction algorithms were applicable to
871–2962 women, depending on the variables required. The prevalence of early
PE was 1.0–1.2% and of late PE was 4.1–5.0% in these patient subsets. One
early PE prediction algorithm performed better than in the original publication
(80% detection rate (DR) of early PE for 10% false-positive rate (FPR)); the
remaining five prediction algorithms underperformed (29–53% DR).
Conclusion: First-trimester prediction algorithms for PE share a high negative
predictive value if applied to an external population but underperform in their
ability to correctly identify women who develop PE. Further research is
required to determine the factors responsible for the suboptimal external
validity
N. Oliveira et al. First-trimester prediction of pre-eclampsia: external validity of algorithms in a prospectively
enrolled cohort. Ultrasound Obstet Gynecol 2014; 44: 279–285 (Baltimora, USA)
31
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
ML LeFevre, U.S.P.S.T.F. Clinical Guideline. Low-Dose Aspirin to
Prevent Morbidity and Mortality From Preeclampsia. Annals of
Internal Medicine. On line: www.annals.org. Sett 2014
Recommendation: The USPSTF recommends the use of low-dose aspirin (81
mg/d) as preventive medication after 12 weeks of gestation in women who
are at high risk for preeclampsia. (B recommendation)
Commento della LG: Evidence did not demonstrate benefit of starting aspirin
earlier (12 to 16 weeks) rather than later (>16 weeks) in pregnancy
Population: This recommendation applies to asymptomatic pregnant women
who are at increased risk for preeclampsia and who have no prior adverse
effects with or contraindications to low-dose aspirin.
32
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Risk Assessment. A chi?
A) Pregnant women are at high risk for preeclampsia if they have 1 or more of
the following risk factors:
• History of preeclampsia, especially when accompanied by an adverse outcome
• Multifetal gestation
• Chronic hypertension
• Type 1 or 2 diabetes
• Renal disease
• Autoimmune disease (i.e., systemic lupus erythematosus, the antiphospholipid
syndrome
Recommend low-dose aspirin if the patient has >1 of these high-risk factors.
33
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Risk Assessment. A chi?
B) Pregnant women are at … moderate-risk … for preeclampsia:
• Nulliparity
• Obesity (body mass index >30 kg/m2)
• Family history of preeclampsia (mother or sister)
• Sociodemographic characteristics (African American race, low socioeconomic
status)
• Age >35 y
• Personal history factors (e.g., low birthweight or small for gestational age,
previous adverse pregnancy outcome, >10-y pregnancy interval)
Consider low-dose aspirin if the patient has several of these moderate-risk factors
34
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Assessment of Risk for Preeclampsia
There are no validated methods of identifying women at high risk for
preeclampsia on the basis of biomarkers, clinical diagnostic tests, or medical
history
35
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
L’utilizzo dei diversi sistemi matematici di «screening» precoce della
preeclampsia è sconsigliato/ignorato da:
•
NICE
•
WHO
•
ACOG
•
USPSTF
•
American Heart Association
•
American Stroke Association
•
American Academy of Family Physicians
FMF (UK) ritiene necessari ulteriori studi per validare lo screening…
36
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
King’s College
2
Resto del Mondo
6
37
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
A prospective cohort of 9,462 pregnancies undergoing first-trimester screening.
Logistic regression predictive models were developed for early and late PE (cut-off
34 weeks’ gestation at delivery). Data included the a priori risk (maternal
characteristics), mean arterial pressure (MAP) and uterine artery (UtA) Doppler
(11-13 weeks) in all cases. Plasma levels (8-11 weeks) of hCG, PAPP-A, placental
growth factor (PlGF) and soluble Fms-like tyrosine kinase-1 (sFlt-1) was analyzed
Results: The best model for early PE (n=57, 0.6%) included a priori risk, MAP, UtA
Doppler, PlGF and sFlt-1 achieving detection rates (DR) of 87.7% and 91.2% for 5%
and 10% false-positive rates (FPR), respectively. For late PE (n=246, 2.6%), the best
model included the a priori risk, MAP, UtA Doppler, PlGF and sFlt-1 achieving DR
of 68.3% and 76.4% at 5% and 10% of FPR, respectively.
Crovetto F et al. First trimester screening for early and late preeclampsia based on maternal
characteristics, biophysical parameters and angiogenic factors. Prenat Diagn. 2014 Oct 24. in press
38
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Uno sguardo alla biochimica:
•
PAPP-A MoM and fß-HCG MoM had no statistically significance for both PE
groups.
•
PlGF was significantly lower in early PE (p<0.001) compared to unaffected
group and to late PE (p<0.001), and in late PE compared to unaffected cases
(p<0.001);
•
sFlt-1 was significantly higher in early PE (p<0.001) and in late PE (p<0.001)
compared to unaffected cases;
•
sFlt-1/PlGF ratio was significantly higher in both PE groups compared to
unaffected (early PE p<0.001, late PE p<0.001), and it was also greater in early
PE compared to late-onset cases (p<0.001).
Crovetto F et al. First trimester screening for early and late preeclampsia based on maternal
characteristics, biophysical parameters and angiogenic factors. Prenat Diagn. 2014 Oct 24. in press
39
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
meno 5 slides…
40
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Sibai BM. First-trimester screening with combined maternal clinical factors, biophysical
and biomarkers to predict preterm pre-eclampsia and hypertensive disorders: are they
ready for clinical use? BJOG 2014; DOI: 10.1111/1471-0528.13052 (Luglio)
… neither the maternal factors nor the serum biomarkers, either alone or
combined, had an adequate detection rate for either all HDP, or GH, or PE
developing at ≥37 weeks of gestation
Using data from the Maternal Fetal Medicine Foundation (MFMF), the use of
combined maternal factors, biophysical and biochemical markers increases the
Detection Rate to 95% for PE requiring delivery at <34 weeks of gestation with
an FPR of 10%. However, the positive predictive value (PPV) for such a screen
remained <10%.
The study by Giguère/Forest, … women at very low risk … They found that a
clinical model that included maternal risk factors, BMI and MAP had a detection
rate of 54% and a PPV of 3% at an FPR of 10% for PE <34 weeks of gestation. 41
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Sibai BM. First-trimester screening with combined maternal clinical factors, biophysical
and biomarkers to predict preterm pre-eclampsia and hypertensive disorders: are they
ready for clinical use? BJOG 2014; DOI: 10.1111/1471-0528.13052 (Luglio)
… given the poor PPV for PE at <34 weeks, and the poor detection rates for all
cases of GH/PE the clinical implications of a PE screen test in the first trimester
remain unclear.
… some authors and commercial screening companies have been promoting a
combination of maternal factors, MAP, uterine artery Doppler and serum
biomarkers obtained in the first trimester as a screening test to identify those at
high risk for developing early-onset PE (95% detection rate with FPR of 10%).
They recommended that women who screen positive will benefit from
receiving low-dose aspirin (LDA) for prevention of early onset PE, as well as
from receiving intensive antenatal monitoring and early intervention.
42
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Sibai BM. First-trimester screening with combined maternal clinical factors, biophysical
and biomarkers to predict preterm pre-eclampsia and hypertensive disorders: are they
ready for clinical use? BJOG 2014; DOI: 10.1111/1471-0528.13052 (Luglio)
However, whether the information provided with this screen will affect patient
outcome or is cost-effective remains unknown. At present, there is no clinical
trial that demonstrates a benefit from using LDA in such a population
A major concern of first-trimester screening for PE without evidence of benefit is
the unintended consequences (conseguenze involontarie!!!)
of those identified as false-positives (97%) of cases for a PPV of 3%.
43
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Sibai BM. First-trimester screening with combined maternal clinical factors, biophysical
and biomarkers to predict preterm pre-eclampsia and hypertensive disorders: are they
ready for clinical use? BJOG 2014; DOI: 10.1111/1471-0528.13052 (Luglio)
Some authors and commercial entities have recommended that those who
screen positive should have:
• more frequent visits,
• more maternal and fetal testing,
• bed rest and other
• interventions that could be potentially harmful to both mother and infant.
Currently, there are no prospective studies or randomised trials evaluating the
benefits and risks of first trimester screening for prediction of PE. Until then,
the use of such tests for screening should remain experimental
44
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Test biochimici e preeclampsia - Conclusioni
• It is understandable that a single biomarker cannot be used as an accurate
predictive tool for diagnosing a complex disorder like PE.
• Therefore, analysis of a set of biomarkers is imperative for early detection of
PE.
• However, the cost of the test, its acceptability at large and its quality control,
are of paramount importance.
• It is hoped that extensive research being done in this arena will ultimately give
rise to affordable diagnostic tools that will allow timely interventions of this
complex disease process
Manisha Kar. Role of Biomarkers in Early Detection of Preeclampsia. Journal of Clinical and
Diagnostic Research. 2014 Apr, Vol-8(4): BE01-BE04
45
Test biochimici: prevedere la preeclampsia
Bergamo, 20 Novembre 2014
Grazie...
46